Hjem › Ulcerøs kolitt › New York › New York City
Kliniske studier for Ulcerøs kolitt i New York City, NY
23 studier for Ulcerøs kolitt søker deltakere på steder i og rundt New York City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
RekruttererFase 2
- New York Gastroenterology Associates - Upper East Side /ID# 281767, New York
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RekruttererFase 1
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
RekruttererFase 3
- New York Gastroenterology Associates ( Site 0253), New York
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RekruttererFase 2
- Pioneer Clinical Research NY, New York
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
RekruttererFase 4
- New York Gastroenterology Associates, New York
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
RekruttererFase 2
- Site 037, New York
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
RekruttererFase 3
- Inflammatory Bowel Disease Center at NYU Langone, New York
- Icahn School of Medicine at Mount Sinai, New York
- Weill Cornell Medical College, New York
- og 2 flere
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
RekruttererFase 2/3
- Columbia University Medical Center, New York
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RekruttererFase 3
- Icahn School of Medicine at Mount Sinai, New York
- New York Gastroenterology Associates, New York
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
RekruttererFase 3
- Icahn School of Medicine at Mount Sinai, New York
A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
RekruttererFase 4
- NYU Langone Health, New York
- Weill Cornell Medical College- New York Presbyterian Hospital, New York
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RekruttererFase 3
- Weill Cornell Medicine - NewYork-Presbyterian Hospital - Site Number: 8400040, New York
- New York Gastroenterology Associates - Site Number: 8400009, New York
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
RekruttererFase 3
- New York Gastroenterology Associates, New York
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
RekruttererFase 2
- Fink Children's Ambulatory Care Center, New York
- Kimmel Pavilion - NYU Langone, New York
- NYU Grossman School of Medicine, New York
- og 4 flere
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
RekruttererFase 2
- Columbia University Medical Center, New York
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RekruttererFase 3
- Manhattan Clinical Research, LLC - Site Number: 8400069, New York
- NYU Langone Health - Site Number: 8400091, New York
- Weill Cornell Medical College - NewYork-Presbyterian Hospital - Site Number: 8400040, New York
- og 2 flere
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
Rekrutterer
- NYU Langone Health, New York
- Cornell University, New York
BOOM-IBD2 Pivotal Clinical Trial
Rekrutterer
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
RekruttererObservasjonsstudie
- New York University, New York
An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis
RekruttererObservasjonsstudie
- NYU Langone Health, New York
- Lenox Hill Hospital, Northwell Health, New York
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
RekruttererFase 3
- New York Presbyterian Hospital, New York
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
RekruttererFase 2
- Mirador Therapeutics Selected Site, New York
Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
RekruttererObservasjonsstudie
- New York University, New York
Ulcerøs kolitt-studier i andre byer
- Orlando, FL22 studier
- Miami, FL21 studier
- Houston, TX17 studier
- San Antonio, TX16 studier
- Tyler, TX15 studier
- Tacoma, WA15 studier
- Chicago, IL15 studier
- San Diego, CA15 studier
- Colorado Springs, CO14 studier
- St. Louis, MO13 studier
- Los Angeles, CA13 studier
- Washington, DC12 studier
Andre studier i New York City
- Brystkreft136 studier
- Ikke-småcellet lungekreft121 studier
- Kreft (alle typer)109 studier
- Prostatakreft103 studier
- Metastatisk kreft93 studier
- Kolorektal kreft78 studier
- Eggstokkreft69 studier
- Lungekreft60 studier
- Multipelt myelom60 studier
- Pankreaskreft60 studier
- Endometriekreft52 studier
- Akut myelogen leukemi51 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.